Research Article
AHCYL1 Is a Novel Biomarker for Predicting Prognosis and Immunotherapy Response in Colorectal Cancer
Figure 3
AHCYL1 knockdown inhibits tumor growth in CRC cancer xenografts. (a) Western blotting analysis of HT-29 cells expressing control (ctrl) or AHCYL1 shRNA. (b, c) HT-29 cells expressing ctrl or AHCYL1 shRNA have been implanted into BALB/c nu/nu mice; (b) tumor growth curve and (c) tumor weights have been measured. (d) Immunohistochemistry (IHC) analysis of CD8 positive T cells in HT-29 xenografts expressing ctrl or AHCYL1 shRNA. Data represents the , per group. .
| (a) |
| (b) |
| (c) |
| (d) |